The Hong Kong stock market's innovative drug sector as a whole lacks new catalysts and is showing weakness: Innovent Biologics rose slightly today, BeiGene was basically flat, CSPC Pharmaceutical Group fell slightly, and Junshi Biosciences also declined; RemeGen fell more than 4%, making it the biggest decliner today, possibly due to profit-taking from previous accumulated gains.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
